| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Bendamustine is a type of DNA cross-linker that can lead to anti-helper function, alkylation, and DNA fragmentation. Bendamustine specifically affects the non-Hodgkin cell transplantation and DNA repair pathways. In SU-DHL-1 cells, bendamustine (50 μM) boosts p53 expression and promotes the NOXA and p21 (Cip1/Waf1) genes. Bendamustine (25 μM) disrupts mitotic checkpoints, leading to hyperplasia during mitosis [1]. Multiple myeloma (MM) cell lines such as RPMI-8226 and 8226-LR5 have lower cell viability when exposed to bendamustine; after 24 hours, the IC25 values of these lines are 101.8 μM and 585.5 μM, and after 48 hours, 51.7 and 374.3 μM, respectively. ..Bendamustine suppresses the spindle formation checkpoint and causes MM cell death triggered by caspase [2].
|
|---|---|
| ln Vivo |
The DoHH-2, Granta 519, and RAMOS models showed 91%, 99%, and 95% inhibition of tumor cell proliferation in response to bendamustine (25 mg/kg, IV). Furthermore, rituximab improved the anticancer impact of bendamustine in the DoHH-2 and RAMOS models, but not in the Granta 519 model [3].
|
| References |
[1]. Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14(1):309-17.
[2]. Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25(5):1108-17. [3]. Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167(4):881-91 |
| Molecular Formula |
C16H21CL2N3O2
|
|---|---|
| Molecular Weight |
358.263
|
| Exact Mass |
357.1011
|
| CAS # |
16506-27-7
|
| Related CAS # |
Bendamustine hydrochloride;3543-75-7;Bendamustine-d4;Bendamustine-d8;1134803-33-0
|
| SMILES |
CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O
|
| Synonyms |
Bendamustine free base; SDX 105; SDX-105; SDX105; Bendamustina; DD6304600; Bendamustinum; Ribomustin. Brand name: Treanda;
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~279.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7913 mL | 13.9563 mL | 27.9127 mL | |
| 5 mM | 0.5583 mL | 2.7913 mL | 5.5825 mL | |
| 10 mM | 0.2791 mL | 1.3956 mL | 2.7913 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
